ライフサイエンスコーパス: PHN

1 PHN occurred in 26 vaccinated men (6.0%) versus 25 unvac

2 PHN risk was not increased.

3 PHN-associated VZV significantly increased sodium curren

4 PHN-associated VZV sodium current increases were therefo

5 PHN-tag influences the production of specific ion types,

6 e vaccine at age 50 years, 25 HZ cases and 1 PHN case could be prevented.

7 enty VZV isolates were studied blind from 11 PHN and 9 non-PHN subjects.

8 old (PWT) decline and microglial activation, PHN-CSF further exacerbated allodynia and triggered both

9 ) against HZ and 45.6% (11.4%-66.6%) against PHN.

10 s clear whether the vaccine protects against PHN among patients who develop HZ despite previous vacci

11 VE against PHN was 0.59 (95% CI 0.21-0.79).

12 des B02.xx plus antiviral within 7 days) and PHN (chart review for HZ-related pain persisting >3 mont

13 perceived a high level of burden from HZ and PHN and generally favored the HZ vaccine.

14 The incidence and severity of HZ and PHN are highest in older adults.

15 , physicians who strongly agreed that HZ and PHN cause significant burden were more likely to recomme

16 nd FM physicians strongly agreed that HZ and PHN caused a significant burden of disease.

17 study examined the incidence rates of HZ and PHN from 1994 to 2018 in the United States to determine

18 study examined the incidence rates of HZ and PHN from 1994-2018 in the United States to determine if

19 s of RZV were effective in preventing HZ and PHN in adults aged >=50 years, with durable protection.

20 ficantly reduced the morbidity due to HZ and PHN in older adults.

21 The incidence and severity of HZ and PHN increase with age in association with an age-related

22 VE against HZ and PHN remained stable over 4 years post-vaccination.

23 e a crucial innovation for preventing HZ and PHN.

24 on would protect older adults against HZ and PHN.

25 Vaccine efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effect

26 fectiveness (VE) against incident zoster and PHN in a general population-based setting.

27 dence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated indiv

28 CSF samples were collected from both PHN patients and non-painful individuals (Control) to as

29 essed 2 and 7 days (NTS), or 10 and 30 days (PHN) later.

30 y-one percent of patients with HZO developed PHN.

31 portion of individuals with HZ who developed PHN was higher from 2007 to 2018 than from 1994 to 2006.

32 famciclovir and placebo groups who developed PHN; the impact of famciclovir treatment on the duration

33 the cinchona alkaloid-derived catalyst DHQD-PHN was clarified by catalyst conformation studies with

34 stereochemical model to rationalize how DHQD-PHN differentiates the two enantiotopic carbonyl groups

35 ree cinchona alkaloid catalysts, namely DHQD-PHN, DHQD-MEQ, and DHQD-CLB, based on calculations of ou

36 Finally, microglial depletion diminished PHN-CSF induced astrogliosis, inflammation and endogenou

37 ion in glial activation and allodynia during PHN, suggesting a potential therapeutic avenue for futur

38 pes of esterification, herein called the EST-PHN approach, provided comparable results, methylation e

39 As expected, PHN-labeled sialylated oligosaccharides with the 2,6-lin

40 Thirty vaccinated women (4.2%) experienced PHN, compared with 75 unvaccinated women (10.4%), with a

41 %) for HZ and 83.7% (95% CI:75.1%-89.3%) for PHN.

42 or uveitis were found to be risk factors for PHN.

43 as higher and better preserved over time for PHN and HZ-associated hospitalizations than for communit

44 In the primary analysis, VE for PHN was 57% (95% CI: 52%-61%) and 45% (95% CI: 36%-53%)

45 tive in scenarios where PHN risk was higher, PHN duration longer, or antiviral shortening of PHN grea

46 th Nav1.6 and Nav1.7 mRNA but not Nav 1.8 in PHN virally infected cells.

47 They identify microbiome alterations in PHN patients, linking microbes and pain sensitivity.

48 BMP4 levels were significantly higher in PHN-CSF compared to Control-CSF (P < 0.001), with a posi

49 rom actin at the onset of podocyte injury in PHN.

50 cation (NC(Ca-ATP)) channels are involved in PHN.

51 to a more dispersed and clustered pattern in PHN.

52 accination is associated with a reduction in PHN.

53 Moreover, PHN-CSF rather than Control-CSF evoked microglial prolif

54 CI) causes progressive hemorrhagic necrosis (PHN), a poorly understood pathological process character

55 ic serum (NTS) or passive Heymann nephritis (PHN) was induced in Sprague-Dawley rats.

56 nous nephropathy (passive Heymann nephritis (PHN)), complement C5b-9-induced proteinuria was associat

57 of proteinuria in passive Heymann nephritis (PHN), a rat model of human membranous nephropathy.

58 Data from both the Pediatric Heart Network (PHN) Single Ventricle Reconstruction (SVR) trial and Ext

59 Post-herpetic neuralgia (PHN) is the most significant complication of herpes zost

60 nce rates of HZ and post-herpetic neuralgia (PHN) since their introduction.

61 nsequences, notably post-herpetic neuralgia (PHN).

62 rpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity in older adults.

63 rrent treatments for postherpetic neuralgia (PHN) have led to the investigation of localised, non-sys

64 Postherpetic neuralgia (PHN) is a common complication of shingles that manifests

65 Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain

66 vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it

67 antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters.

68 ence rates of HZ and postherpetic neuralgia (PHN) since their introduction.

69 of the microbiota in postherpetic neuralgia (PHN), a chronic pain condition resulting from varicella-

70 tion are at risk for postherpetic neuralgia (PHN), a painful and long-lasting complication.

71 llness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for the STPS pop

72 rpes zoster (HZ) and postherpetic neuralgia (PHN), intentions for recommending the HZ vaccine, and pe

73 During postherpetic neuralgia (PHN), the cerebral spinal fluid (CSF) possesses the capa

74 litating pain called postherpetic neuralgia (PHN), which can last for months after the disappearance

75 painful condition of postherpetic neuralgia (PHN), which has been difficult to treat because the unde

76 t on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting after rash he

77 lmic zoster (OZ) and postherpetic neuralgia (PHN).

78 rpes zoster (HZ) and postherpetic neuralgia (PHN).

79 risk and the risk of postherpetic neuralgia (PHN).

80 many of whom develop postherpetic neuralgia (PHN).

81 and chronic pain, or postherpetic neuralgia (PHN).

82 group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of zoster (group 3) reveale

83 ion in cultured primary hippocampal neurons (PHNs).

84 provide insight into the development of new PHN therapies.

85 tes were studied blind from 11 PHN and 9 non-PHN subjects.

86 tude in the cell line when compared with non-PHN VZV, wild-type (Dumas) or vaccine VZV strains ((POka

87 ion into the posterior hypothalamic nucleus (PHN).

88 Sites using public health nurses (PHNs) started more high-risk TST(-) contacts on presumpt

89 Four days after immunization, 58% of PHN rats had mild proteinuria.

90 decline of total nephrin on days 4 and 7 of PHN as well as a reduction in the actin-associated fract

91 y endothelium are critical to development of PHN and constitute a major target for therapy in SCI.

92 of famciclovir treatment on the duration of PHN, while controlling for significant covariates; and t

93 -69.1%; P<.001) and reduced the incidence of PHN by 66.5% (95% CI, 47.5%-79.2%; P<.001).

94 50.1%, vaccine efficacy for the incidence of PHN decreased from 66.5% to 60.1%, and vaccine efficacy

95 The incidence of PHN was compared between vaccinated and unvaccinated -pa

96 The secondary end point was the incidence of PHN.

97 iva is the outcome of zoster, independent of PHN.

98 HZ to prevent PHN, and the intractability of PHN, the advent of the HZ vaccine appears to be a crucia

99 iated with the development or persistence of PHN at 6, 12, or 26 weeks.

100 remia and the development and persistence of PHN.

101 ignificant covariates; and the prevalence of PHN at monthly intervals from 30 to 180 days after enrol

102 reduces both the duration and prevalence of PHN.

103 le in the glial modulation in the process of PHN.

104 The overall incidence rate of PHN was 57.5 (95% CI, 56.0-59.0) cases per 100 000 perso

105 The overall incidence rate of PHN was 57.5 (95% CI: 56.0, 59.0) cases per 100 000 pers

106 ccination is associated with a lower risk of PHN in women but not in men.

107 duration longer, or antiviral shortening of PHN greater.

108 imitation (P limitation) or during growth on PHN compared with their rates in the cultures with Pi we

109 eins responding to P limitation or growth on PHN was 30 to 40% of the cells' total mass.

110 imitation with those responding to growth on PHN, one can speculate which proteins are likely involve

111 ere VZV infections but have little impact on PHN.

112 Demographic data and information on PHN were collected electronically.

113 for 365 days with no prior history of HZ or PHN.

114 or >=365 days with no prior history of HZ or PHN.

115 Pi were classified as belonging to the PL or PHN stimulon, respectively.

116 work, we propose utility of phenylhydrazine (PHN) labeling for structural studies of fucosylated N-gl

117 we present the advantage of phenylhydrazine (PHN) labeling for the detection and efficient discrimina

118 tization in comparison with phenylhydrazine (PHN) derivatization.

119 tate growth in media containing phosphonate (PHN) as the sole P source was examined by two-dimensiona

120 ficulty of adequately treating HZ to prevent PHN, and the intractability of PHN, the advent of the HZ

121 pain severity are risk factors for prolonged PHN.

122 The Pediatric Heart Network's (PHN) single ventricle reconstruction (SVR) trial compare

123 a lactone were detected carrying the second PHN unit.

124 The PHN stimulon was smaller: it included 257 proteins; 227

125 On day 7, the PHN rats were severely proteinuric, and most slit diaphr

126 New data from the PHN are now beginning to show equipoise for the two pall

127 NPY-evoked cardiovascular responses from the PHN by determining the rank order of potency of several

128 r respective cardiovascular changes from the PHN with NPY stimulating the Y(1) receptor.

129 Y(1) receptor antagonist BIBP 3226 into the PHN prior to NPY completely blocked the cardiovascular r

130 tide YY (PYY) or CCh microinjection into the PHN.

131 roglial depletion was performed prior to the PHN-CSF intervention so as to elucidate the microglia-as

132 ntagonist-Stattic were employed to treat the PHN-CSF or exogenous BMP4 challenged cultured astrocytes

133 been proposed to be a factor contributing to PHN.

134 considered cost effective in scenarios where PHN risk was higher, PHN duration longer, or antiviral s

135 nfection in vitro study to determine whether PHN-associated VZV isolates induce changes in sodium ion

136 pain and sleep interference associated with PHN.

137 one application of NGX-4010 in patients with PHN.

138 tivated in glomeruli isolated from rats with PHN.

139 ts with a history of zoster, with or without PHN (21 [67%] of 32 subjects in groups 1 and 2), than in